Tricida, Inc. is a pharmaceutical company headquartered in South San Francisco, California. Its main focus lies on developing and commercializing veverimer (TRC101), an orally-administered polymer. Veverimer (TRC101) is currently in the Phase III trial phase and is designed to treat metabolic acidosis in patients with chronic kidney disease by removing acid from the gastrointestinal track.